Manish R. Patel

Centers for Disease Control and Prevention

Also affiliated with National Center for Immunization and Respiratory Diseases, Westmead Hospital, Sarah Cannon

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 14 papers. Top paper: “The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia”.

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

Nature(2023)10.1038/s41586-023-05812-3

N/A

5.2DataRank · unranked

480 citations

Ibrahim Aldoss, John F. Dipersio, Branko Cuglievan, Richard M. Stone, Martha Arellano +19 more

Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer

British Journal of Cancer(2020)10.1038/s41416-020-01041-x

N/A

2.6DataRank · unranked

90 citations

Michael S. Gordon, Monica Mita, Brian I. Rini, Vicky Makker, Teresa Macarulla +15 more

Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial

Blood(2024)10.1182/blood.2024024510

N/A

0.874DataRank · unranked

27 citations

Jennifer A. Woyach, Chan Y. Cheah, Catherine C. Coombs, Nirav N. Shah, William G. Wierda +13 more

Comparison of risankizumab and apremilast for the treatment of adults with moderate plaque psoriasis eligible for systemic therapy: results from a randomized, open-label, assessor-blinded phase IV study (IMMpulse)

British Journal of Dermatology(2023)10.1093/bjd/ljad252

N/A

0.662DataRank · unranked

22 citations

Jerry Bagel, Stephen K. Tyring, Hwanhee Hong, Lev Pavlovsky, Ronald Vender +11 more

First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma

Molecular Cancer Therapeutics(2023)10.1158/1535-7163.mct-23-0065

N/A

0.500DataRank · unranked

27 citations

Judy S. Wang, Amit M. Oza, Manish R. Patel, Susanna V. Ulahannan, Todd M. Bauer +12 more

Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies

Leukemia(2025)10.1038/s41375-025-02515-8

N/A

0.396DataRank · unranked

13 citations

Xiaoli Mi, Bin Lü, Andrew Kuykendall, David A. Sallman, Manish R. Patel +16 more

513O A phase I/II multicenter, first-in-human study of DS-7300 (B7-H3 DXd-ADC) in patients (pts) with advanced solid tumors

Annals of Oncology(2021)10.1016/j.annonc.2021.08.1035

N/A

0DataRank · unranked

6 citations

Toshihiko Doi, Sarina A. Piha‐Paul, Shiraj Sen, Toshio Shimizu, Bi‐Hua Cheng +10 more

Serial monitoring of genomic alterations in circulating tumor cells of ER‐positive/HER2‐negative advanced breast cancer: feasibility of precision oncology biomarker detection

Molecular Oncology(2021)10.1002/1878-0261.13150

N/A

0DataRank · unranked

21 citations

Emily M. Dolce, Elizabeth P. Darga, Kevin Hu, Chia‐Jen Liu, Jackie Pierce +27 more

A cross‐sectional study of ageing at the mouse neuromuscular junction and effects of an experimental therapeutic approach for dynapenia

The Journal of Physiology(2023)10.1113/jp284749

N/A

0DataRank · unranked

7 citations

Manish R. Patel, Jude K. Baroudi, Minghua Wu, S. Gatti, M. Liang +4 more

Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-2972

N/A

0DataRank · unranked

58 citations

Nizar M. Tannir, Othon Iliopoulos, Richard J. Lee, Melinda L. Telli, Alice C. Fan +15 more

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA -Mutant Cancers

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2657

N/A

0DataRank · unranked

39 citations

Matthew T. Chang, Dejan Juric, Cristina Saura, Valentina Gambardella, Anton Melnyk +16 more

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial

Haematologica(2024)10.3324/haematol.2024.285754

N/A

0DataRank · unranked

13 citations

Michael Wang, Lindsey E. Roeker, Krish Patel, Jennifer A. Woyach, William G. Wierda +30 more

Data from Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial

(2023)10.1158/1078-0432.c.6532368.v1

N/A

0DataRank · unranked

0 citations

Nizar M. Tannir, Othon Iliopoulos, Richard J. Lee, Melinda L. Telli, Alice C. Fan +15 more

Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3261

N/A

0DataRank · unranked

30 citations

Manish R. Patel, John M. Burke, Ranjana H. Advani, Bruce D. Cheson, Jeff P. Sharman +11 more